Induction toxicity in childhood acute lymphoblastic leukemia: A comparison of two schedules of daunorubicin administration
- 1 January 1995
- journal article
- research article
- Published by Wiley in Medical and Pediatric Oncology
- Vol. 24 (1) , 18-22
- https://doi.org/10.1002/mpo.2950240105
Abstract
The haematological toxicity of the induction phase of chemotherapy for acute lymphoblastic leukaemia (ALL) was compared in two cohorts of patients. The principal difference between these two cohorts was the mode of administration of the anthracycline, daunorubicin (DNR). Both groups received four-drug induction chemotherapy, which produced a high remission rate. Those receiving DNR on days 1 and 2 experienced a profound but shorter period of neutropenia and more severe thrombocytopenia than those who received the DNR weekly. The pattern of hospitalisation and support facilities in the individual unit may determine which regimen is to be preferred. These observations are relevant for the newly diagnosed patient in whom an anthracycline is retained in the induction therapy for ALL.Keywords
This publication has 7 references indexed in Scilit:
- Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse: The memorial Sloan-Kettering-New York-II protocolCancer, 1993
- Anaplastic large cell lymphoma in childhoodMedical and Pediatric Oncology, 1993
- Acute Lymphoblastic LeukaemiaPublished by Springer Nature ,1992
- Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (Report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood)British Journal of Haematology, 1991
- Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting featuresMedical and Pediatric Oncology, 1990
- Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group.Journal of Clinical Oncology, 1989
- The impact of induction anthracycline on long‐term failure‐free survival in childhood acute lymphoblastic leukemiaMedical and Pediatric Oncology, 1986